Skip to main content
SpringerLink
Log in
Book cover

32nd Hemophilia Symposium pp 164–167Cite as

A Life-threatening Cardiomyopathy following Port-a-Cath Infection under Immune Tolerance Therapy

  • Conference paper

  • 103 Accesses

Abstract

For elimination of inhibitors against factor VIII immune tolerance therapy (Bonnor Malmö-protocol) is Mainly used. It requires intravenous injections twice daily up to several Months — while in early infancy antibodies Mostly appear within the first 36 days of treatment [6]. Therefore, in patients with inhibitors or on prophylactic treatment, Port insertion is increasingly recommended (Fig. 1). We describe a particularly complicated case.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bontempo FA, Lewis JH, Spero JA, Ragni MV, Kiss JE, Petroski CJ, Thompson ME, Hardesty RL, Kormos RL, Griffith BP. Heart transplant in a hemophiliac with an acquired factor VIII inhibitor: Synthesis of factor VIII:C in pericardial fluid. Transplant Proc 1988; 20: 790–791.

    Google Scholar 

  2. Brincker H, Saeter G. Fifty-five patient years’ experience with a totally implanted system for intravenous chemotherapy. Cancer 1986; 57: 1124–1129.

    Article  PubMed  CAS  Google Scholar 

  3. Collins PW, Khair KS, Liesner R, Hann IM. Complications experienced with central venous catheters in children with congenital bleeding disorders. Br I Haematol 1997; 99: 206–208.

    Article  CAS  Google Scholar 

  4. Ghosh K, Shetty S, Mohanty D. Milder clinical presentation of haemophilia A with severe deficiency of factor VIII as Measured by one-stage assay. Haemophilia 2001; 7: 9–12.

    Article  PubMed  CAS  Google Scholar 

  5. Groeger JS, Lucas AB, Thaler HT, Friedlander-Klar H, Brown AE, Kiehn TE, Armstrong D. Infectious Morbidity associated with long-term use of venous access devices in patients with cancer. Ann Intern Med 1993; 119: 1168–1174.

    PubMed  CAS  Google Scholar 

  6. Kreuz W, Escuriola-Ettingshausen C, Martinez-Saguer I, Gungor T, Kornhuber B. Epidemiology of inhibitors in haemophilia A. Vox Sang 1996; 70: 2–8.

    Article  PubMed  Google Scholar 

  7. Laffer U, DÜrig M, Bloch HR, Zuber M, Stoll HR. IMplantable catheter systems. Experience with 205 patients. Dtsch Med Wochenschr 1989; 114: 655–658.

    Article  PubMed  CAS  Google Scholar 

  8. Ljung R, Petrini P, Nilsson IM. Diagnostic symptoms of severe and Moderate haemophilia A and B. A survey of 140 cases. Acta Paediatr Scand 1990; 79: 196–200.

    Article  PubMed  CAS  Google Scholar 

  9. Ljung R, Van Den Berg M, Petrini P, Tengborn L, Scheibel E, Kekomaki R, Effenberger W. Port-A-Cath usage in children with haemophilia: experience of 53 cases. Acta Paediatr 1998;87: 1051–1054.

    Article  PubMed  CAS  Google Scholar 

  10. Oldenburg J, Brackmann HH, Schwaab R. Risk factors for inhibitor development in hemophilia A. Haematologica 2000; 85: 7–13.

    PubMed  CAS  Google Scholar 

  11. Salzman MB, Rubin LG. Intravenous catheter-related infections. Adv Pediatr Infect Dis 1995; 10: 337–368.

    PubMed  CAS  Google Scholar 

  12. Santagostino E, Gringeri A, Muça-Perja M, Mannucci PM. A prospective clinical trial of implantable central venous access in children with haemophilia. Br J Haematol 1998; 102: 1224–1228.

    Article  PubMed  CAS  Google Scholar 

  13. Schwartz C, Henrickson KJ, Roghmann K, Powell K. Prevention of bacteremia attributed to luminal colonization of tunneled central venous catheters with vancomycin-susceptible organisms. J Clin Oncol. 1990; 8: 1591–1597.

    PubMed  CAS  Google Scholar 

  14. Sheth S, DiMichele D, Lee M, Lamour J, Quaegebeur J, Hsu D, Addonizio L, Piomelli S. Heart transplant in a factor Vlll-deficient patient with a high-titre inhibitor: perioperative Management using high-dose continuous infusion factor VIII and recombinant factor VIIa. Haemophilia 2001; 7: 227–232.

    Article  PubMed  CAS  Google Scholar 

  15. Van Den Berg HM, Fischer K, Roosendaal G, Mauser-Bunschoten EP. The use of the Port-A-Cath in children with haemophilia — a review. Haemophilia 1998; 4: 418–420.

    Article  Google Scholar 

  16. Weidmann B, Hanseler T, Jimenez C, Niederle N. Tricuspid endocarditis by implantable venous access. J Clin Oncol 1994; 12: 1103–1105.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. G. Wiegand
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Rauch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. Effenberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H.-H. Brackmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Hofbeck
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Hemophilia Center, Dept. of Internal Medicine, University Hospital, Theodor-Stern-Kai 7, D-60590, Frankfurt am Main, Germany

    Inge Scharrer

  2. Dept. of Hemostasiology, University Hospital, Ziemssenstr. 1a, D-80336, München, Germany

    Wolfgang Schramm

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Wiegand, G., Rauch, R., Effenberger, W., Brackmann, HH., Hofbeck, M. (2003). A Life-threatening Cardiomyopathy following Port-a-Cath Infection under Immune Tolerance Therapy. In: Scharrer, I., Schramm, W. (eds) 32nd Hemophilia Symposium. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18150-4_24

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-18150-4_24

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-43884-7

  • Online ISBN: 978-3-642-18150-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation